Sargent Investment Group LLC Invests $455,000 in Gilead Sciences, Inc. (NASDAQ:GILD)

Sargent Investment Group LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 5,054 shares of the biopharmaceutical company's stock, valued at approximately $455,000.

A number of other hedge funds have also modified their holdings of the stock. nVerses Capital LLC acquired a new position in Gilead Sciences in the 3rd quarter worth approximately $25,000. HHM Wealth Advisors LLC lifted its holdings in shares of Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 154 shares in the last quarter. Valued Wealth Advisors LLC boosted its position in shares of Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 161 shares during the period. Decker Retirement Planning Inc. purchased a new position in shares of Gilead Sciences during the fourth quarter valued at $29,000. Finally, Crews Bank & Trust acquired a new position in Gilead Sciences during the fourth quarter valued at $31,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

GILD has been the topic of several research analyst reports. Wells Fargo & Company lifted their target price on Gilead Sciences from $100.00 to $105.00 and gave the company an "overweight" rating in a research note on Thursday, November 7th. Truist Financial boosted their price objective on shares of Gilead Sciences from $83.00 to $97.00 and gave the company a "hold" rating in a research report on Friday, November 8th. Cantor Fitzgerald reissued a "neutral" rating and set a $80.00 target price on shares of Gilead Sciences in a research note on Wednesday, December 11th. The Goldman Sachs Group upped their price target on shares of Gilead Sciences from $74.00 to $84.00 and gave the stock a "neutral" rating in a research note on Thursday, November 7th. Finally, Royal Bank of Canada reiterated a "sector perform" rating and set a $84.00 price objective on shares of Gilead Sciences in a report on Monday, February 3rd. Eleven investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $98.39.

Insider Activity at Gilead Sciences

In other news, Director Jeffrey Bluestone sold 6,788 shares of the business's stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the sale, the director now directly owns 8,920 shares in the company, valued at approximately $815,198.80. The trade was a 43.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 142,180 shares of the firm's stock in a transaction on Friday, January 31st. The stock was sold at an average price of $97.22, for a total value of $13,822,739.60. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares of the company's stock, valued at approximately $12,626,253.06. This trade represents a 52.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 572,824 shares of company stock worth $53,611,715 in the last ninety days. 0.16% of the stock is currently owned by insiders.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD traded down $2.00 during trading hours on Friday, hitting $96.04. 7,182,199 shares of the company's stock were exchanged, compared to its average volume of 6,866,207. The company's 50-day moving average price is $93.04 and its 200-day moving average price is $86.76. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $100.51. The stock has a market capitalization of $119.69 billion, a price-to-earnings ratio of 1,067.11, a PEG ratio of 1.25 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping analysts' consensus estimates of $1.58 by $0.44. The company had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company's quarterly revenue was up 7.0% compared to the same quarter last year. During the same period in the previous year, the company earned $2.29 earnings per share. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 4.35 earnings per share for the current fiscal year.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.